A US FDA advisory committee’s views on the development and implementation of a list of pediatric cancer molecular targets also could influence how studies among multiple agents in the same class are prioritized and coordinated on a global basis.
The Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet June 20 to review FDA’s proposed lists of molecular targets considered to be substantially relevant, or not relevant,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?